JP2012526149A - ワクチン増強剤としてのαチモシンペプチド - Google Patents
ワクチン増強剤としてのαチモシンペプチド Download PDFInfo
- Publication number
- JP2012526149A JP2012526149A JP2012510041A JP2012510041A JP2012526149A JP 2012526149 A JP2012526149 A JP 2012526149A JP 2012510041 A JP2012510041 A JP 2012510041A JP 2012510041 A JP2012510041 A JP 2012510041A JP 2012526149 A JP2012526149 A JP 2012526149A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- vaccination
- thymosin peptide
- administered
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 222
- 108010046075 Thymosin Proteins 0.000 title claims abstract description 134
- 239000003623 enhancer Substances 0.000 title 1
- 238000002255 vaccination Methods 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 52
- 229960003971 influenza vaccine Drugs 0.000 claims abstract description 30
- 206010061598 Immunodeficiency Diseases 0.000 claims abstract description 9
- 108010078233 Thymalfasin Proteins 0.000 claims description 134
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical group CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims description 132
- 229960004231 thymalfasin Drugs 0.000 claims description 131
- 206010022000 influenza Diseases 0.000 claims description 39
- 102000007501 Thymosin Human genes 0.000 claims description 35
- 241000700605 Viruses Species 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 12
- 238000001631 haemodialysis Methods 0.000 claims description 12
- 230000000322 hemodialysis Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 230000028993 immune response Effects 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 229960002520 hepatitis vaccine Drugs 0.000 claims description 7
- 238000010255 intramuscular injection Methods 0.000 claims description 6
- 239000007927 intramuscular injection Substances 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000012678 infectious agent Substances 0.000 claims description 5
- 201000008827 tuberculosis Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 4
- 108010041986 DNA Vaccines Proteins 0.000 claims description 4
- 229940021995 DNA vaccine Drugs 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 4
- 201000007930 alcohol dependence Diseases 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 229940124551 recombinant vaccine Drugs 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 229940031626 subunit vaccine Drugs 0.000 claims description 4
- 229940031572 toxoid vaccine Drugs 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 241000606161 Chlamydia Species 0.000 claims description 3
- 241000701022 Cytomegalovirus Species 0.000 claims description 3
- 206010013654 Drug abuse Diseases 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 3
- 241000711549 Hepacivirus C Species 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 241000709721 Hepatovirus A Species 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 208000016604 Lyme disease Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 201000005702 Pertussis Diseases 0.000 claims description 3
- 206010035148 Plague Diseases 0.000 claims description 3
- 208000000474 Poliomyelitis Diseases 0.000 claims description 3
- 206010037742 Rabies Diseases 0.000 claims description 3
- 206010043376 Tetanus Diseases 0.000 claims description 3
- 208000037386 Typhoid Diseases 0.000 claims description 3
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 206010013023 diphtheria Diseases 0.000 claims description 3
- 229940037467 helicobacter pylori Drugs 0.000 claims description 3
- 230000007813 immunodeficiency Effects 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 201000008297 typhoid fever Diseases 0.000 claims description 3
- 206010027249 Meningitis meningococcal Diseases 0.000 claims description 2
- 201000010924 Meningococcal meningitis Diseases 0.000 claims description 2
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 claims description 2
- 206010035728 Pneumonia pneumococcal Diseases 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 230000009395 genetic defect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 208000022218 streptococcal pneumonia Diseases 0.000 claims description 2
- 206010008631 Cholera Diseases 0.000 claims 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 2
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 201000005807 Japanese encephalitis Diseases 0.000 claims 2
- 241000710842 Japanese encephalitis virus Species 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000003152 Yellow Fever Diseases 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 210000002418 meninge Anatomy 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 230000001681 protective effect Effects 0.000 abstract description 15
- 101800001530 Thymosin alpha Proteins 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 29
- 238000002347 injection Methods 0.000 description 25
- 239000007924 injection Substances 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 230000004044 response Effects 0.000 description 18
- 229940124893 Fluvirin Drugs 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000282339 Mustela Species 0.000 description 8
- 208000020832 chronic kidney disease Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 206010064097 avian influenza Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000001932 seasonal effect Effects 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 208000002979 Influenza in Birds Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 201000010740 swine influenza Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 230000016784 immunoglobulin production Effects 0.000 description 5
- 206010069767 H1N1 influenza Diseases 0.000 description 4
- 241000282341 Mustela putorius furo Species 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 201000000523 end stage renal failure Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229960000172 trivalent influenza vaccine Drugs 0.000 description 4
- 229940124896 Fluarix Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 208000030212 nutrition disease Diseases 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940124963 Afluria Drugs 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940124901 Comvax Drugs 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229940124894 Fluzone Drugs 0.000 description 2
- 229940124914 Havrix Drugs 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 2
- 229940124908 Pediarix Drugs 0.000 description 2
- 108700033496 Recombivax HB Proteins 0.000 description 2
- 229940124942 Recombivax HB Drugs 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 229940124922 Twinrix Drugs 0.000 description 2
- 229940124937 Vaqta Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 208000037799 influenza C Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000031951 Primary immunodeficiency Diseases 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000011832 ferret model Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 229940124866 human papillomavirus vaccine Drugs 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 229940029583 inactivated polio vaccine Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940031960 pneumococcal polysaccharide vaccine Drugs 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940034080 provenge Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 229960002109 tuberculosis vaccine Drugs 0.000 description 1
- 229960001515 yellow fever vaccine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17662509P | 2009-05-08 | 2009-05-08 | |
| US61/176,625 | 2009-05-08 | ||
| US23793209P | 2009-08-28 | 2009-08-28 | |
| US61/237,932 | 2009-08-28 | ||
| US32315510P | 2010-04-12 | 2010-04-12 | |
| US61/323,155 | 2010-04-12 | ||
| PCT/US2010/034221 WO2010129947A2 (en) | 2009-05-08 | 2010-05-10 | Alpha thymosin peptides as vaccine enhancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057490A Division JP5766894B2 (ja) | 2009-05-08 | 2015-03-20 | ワクチン増強剤としてのαチモシンペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526149A true JP2012526149A (ja) | 2012-10-25 |
| JP2012526149A5 JP2012526149A5 (cg-RX-API-DMAC10.html) | 2015-05-14 |
Family
ID=43050921
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510041A Withdrawn JP2012526149A (ja) | 2009-05-08 | 2010-05-10 | ワクチン増強剤としてのαチモシンペプチド |
| JP2015057490A Active JP5766894B2 (ja) | 2009-05-08 | 2015-03-20 | ワクチン増強剤としてのαチモシンペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015057490A Active JP5766894B2 (ja) | 2009-05-08 | 2015-03-20 | ワクチン増強剤としてのαチモシンペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8716012B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2427213B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2012526149A (cg-RX-API-DMAC10.html) |
| CN (1) | CN102458470B (cg-RX-API-DMAC10.html) |
| ES (1) | ES2537785T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2010129947A2 (cg-RX-API-DMAC10.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014532620A (ja) * | 2011-10-20 | 2014-12-08 | ノバルティス アーゲー | 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン |
| WO2026105307A1 (ja) * | 2024-11-15 | 2026-05-21 | 公益財団法人東京都医学総合研究所 | エムポックスワクチン |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006062917A2 (en) * | 2004-12-06 | 2006-06-15 | Sciclone Pharmaceuticals, Inc. | Alpha thymosin peptides as cancer vaccine adjuvants |
| WO2012109106A1 (en) * | 2011-02-09 | 2012-08-16 | Sciclone Pharmaceuticals, Inc. | Thymosin alpha peptide for preventing, reducing the severity of, and treating infection |
| US20130296223A1 (en) * | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| CN103145853B (zh) * | 2013-03-05 | 2014-06-11 | 河南科技大学 | 重组Tα1-BP5融合肽、基因、工程菌及应用 |
| CN109793891A (zh) * | 2017-11-17 | 2019-05-24 | 韩震 | 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法 |
| CN112239784A (zh) * | 2019-07-19 | 2021-01-19 | 首都医科大学附属北京佑安医院 | Ifitm3多态性在制备检测老年肾透析患者分泌h3n2抗体水平产品中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8018A (en) * | 1851-04-01 | Improvement in seed-planters | ||
| JP2005506997A (ja) * | 2001-10-26 | 2005-03-10 | ロード・アイランド・ホスピタル | 遺伝的免疫化のチモシン増強 |
| JP2008523067A (ja) * | 2004-12-06 | 2008-07-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 癌ワクチンアジュバントとしてのαサイモシンペプチド |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4077949A (en) * | 1973-12-28 | 1978-03-07 | Sloan-Kettering Institute For Cancer Research | Polypeptide hormones of the thymus |
| DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
| US4079127A (en) * | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
| DE3100974A1 (de) * | 1980-01-18 | 1982-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente |
| US4612365A (en) * | 1980-03-25 | 1986-09-16 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften | Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments |
| US4293455A (en) * | 1980-04-07 | 1981-10-06 | Rockefeller University | N.sup.α -Desacetylthymosinα1 and process |
| US4560676A (en) * | 1980-04-07 | 1985-12-24 | The Rockefeller University | N.sup.α -desacetylthymosinα1 and process |
| US4361673A (en) * | 1980-09-19 | 1982-11-30 | American Home Products Corporation | Polypeptide compositions |
| US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| US6106868A (en) * | 1990-08-24 | 2000-08-22 | The Board Of Governors Of Wayne State University | Method for the treatment of hepatitis |
| TW224053B (cg-RX-API-DMAC10.html) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| US5308833A (en) * | 1992-02-06 | 1994-05-03 | Sciclone Pharmaceuticals | Method for treating hepatitis B carriers with minimal disease |
| US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| US5432165A (en) * | 1992-04-06 | 1995-07-11 | Oclassen Pharmaceuticals, Inc. | Methods for the treatment of infection caused by Hepatitis B virus (HBV) |
| AU4671193A (en) | 1992-07-13 | 1994-01-31 | Kenneth E. Sherman | Composition and method of treating hepatitis b |
| CN1094310A (zh) | 1992-12-15 | 1994-11-02 | 托马斯·C·梅里根 | 人体免疫缺陷性病毒感染用组合式化学疗法 |
| CN1072961C (zh) | 1993-03-05 | 2001-10-17 | 施塞克龙药品公司 | 治疗对干扰素治疗无反应者的丙型肝炎的方法 |
| US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
| US5468729A (en) * | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
| US5750501A (en) * | 1993-11-05 | 1998-05-12 | Alpha 1 Biomedicals, Inc. | Method and composition for treatment of patients having decompensated liver disease |
| AU685413B2 (en) | 1993-11-05 | 1998-01-22 | Board Of Governors Of Wayne State University, The | Method and composition for treatment of patients having decompensated liver disease |
| US5888980A (en) | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5880980A (en) * | 1996-09-30 | 1999-03-09 | Rockwell International Corporation | Distributed decimation sample rate conversion |
| US5939423A (en) | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| PT903148E (pt) | 1997-09-21 | 2002-02-28 | Schering Corp | Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| DE69901321T2 (de) | 1998-05-15 | 2002-12-12 | Schering Corp., Kenilworth | Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US20050037018A1 (en) * | 2003-06-20 | 2005-02-17 | Innogentics N.V. | HCV combination therapy |
| US6288033B1 (en) | 1998-09-25 | 2001-09-11 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir |
| US7208167B2 (en) * | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| AU8353601A (en) | 2000-08-07 | 2002-02-18 | Sciclone Pharmaceuticals Inc | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| WO2003035111A1 (en) * | 2001-10-24 | 2003-05-01 | Sciclone Pharmaceuticals, Inc. | Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| JP2005510491A (ja) * | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス， インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
| UA80957C2 (en) * | 2001-11-01 | 2007-11-26 | Sciclone Pharmaceuticals Inc | Method of administering a thymosin alpha 1 peptide |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| KR20060013515A (ko) * | 2003-04-23 | 2006-02-10 | 사이클론 파아머슈티컬 인코오퍼레이티드 | 알파 티모신 펩티드에 의한 호흡기 바이러스 감염 치료또는 예방 |
| CN100341571C (zh) * | 2005-09-16 | 2007-10-10 | 孙介光 | 一种治疗肿瘤的药物及该药物在制备治疗肿瘤药物中应用 |
| JP5441685B2 (ja) * | 2006-05-02 | 2014-03-12 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | チモシンα１の、単独またはＰＴＸ３またはガンシクロビルとの組合せにおける、サイトメガロウイルス感染の処置のための使用 |
| BRPI0712595A2 (pt) * | 2006-05-19 | 2012-07-03 | Sigma Tau Ind Farmaceuti | uso de timosina alfa 1 para o tratamento de doenças imunológicas. |
| JP2011506467A (ja) * | 2007-12-14 | 2011-03-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 |
-
2010
- 2010-05-10 JP JP2012510041A patent/JP2012526149A/ja not_active Withdrawn
- 2010-05-10 EP EP10772928.7A patent/EP2427213B1/en active Active
- 2010-05-10 ES ES10772928.7T patent/ES2537785T3/es active Active
- 2010-05-10 WO PCT/US2010/034221 patent/WO2010129947A2/en not_active Ceased
- 2010-05-10 US US12/776,976 patent/US8716012B2/en active Active
- 2010-05-10 CN CN201080030714.7A patent/CN102458470B/zh active Active
-
2015
- 2015-03-20 JP JP2015057490A patent/JP5766894B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8018A (en) * | 1851-04-01 | Improvement in seed-planters | ||
| JP2005506997A (ja) * | 2001-10-26 | 2005-03-10 | ロード・アイランド・ホスピタル | 遺伝的免疫化のチモシン増強 |
| JP2008523067A (ja) * | 2004-12-06 | 2008-07-03 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | 癌ワクチンアジュバントとしてのαサイモシンペプチド |
Non-Patent Citations (1)
| Title |
|---|
| JPN6014024061; Ｗｉｌｌｉａｍ Ｂ． Ｅｒｓｈｌｅｒ ｅｔ ａｌ: Ａｎｎａｌｓ ｏｆ ｔｈｅ Ｎｅｗ Ｙｏｒｋ Ａｃａｄｅｍｙ ｏｆ Ｓｃｉｅｎｃｅｓ １１１２, 2007, ｐ．３７５-３８４ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014532620A (ja) * | 2011-10-20 | 2014-12-08 | ノバルティス アーゲー | 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン |
| WO2026105307A1 (ja) * | 2024-11-15 | 2026-05-21 | 公益財団法人東京都医学総合研究所 | エムポックスワクチン |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2427213A4 (en) | 2013-08-21 |
| WO2010129947A2 (en) | 2010-11-11 |
| JP2015134808A (ja) | 2015-07-27 |
| HK1170669A1 (zh) | 2013-03-08 |
| US8716012B2 (en) | 2014-05-06 |
| US20100285060A1 (en) | 2010-11-11 |
| JP5766894B2 (ja) | 2015-08-19 |
| CN102458470A (zh) | 2012-05-16 |
| WO2010129947A3 (en) | 2011-03-10 |
| CN102458470B (zh) | 2016-01-20 |
| EP2427213A2 (en) | 2012-03-14 |
| EP2427213B1 (en) | 2015-04-01 |
| ES2537785T3 (es) | 2015-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5766894B2 (ja) | ワクチン増強剤としてのαチモシンペプチド | |
| US7914797B2 (en) | Influenza vaccine | |
| ES2643646T3 (es) | Vectores de vacuna y métodos para potenciar las respuestas inmunitarias | |
| CN113454102A (zh) | 非洲猪瘟疫苗 | |
| AU2010201905A1 (en) | Composition for adjuvant containing poly-gamma-glutamic acid | |
| CN109701010B (zh) | 疫苗复合佐剂系统及其在抗原中的应用 | |
| KR20130048208A (ko) | 인플루엔자 백신 | |
| Lu et al. | Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus | |
| CA2722558A1 (en) | Methods for preparing immunogenic compositions | |
| US20240415949A1 (en) | Mucosal vaccine, methods of use and administration thereof | |
| JP2011524372A (ja) | インフルエンザワクチン接種のための新規ペプチドアジュバント | |
| CN103517713A (zh) | 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽 | |
| CN107693788B (zh) | 一种用于预防或治疗乙型肝炎的药物组合物及其用途 | |
| EP2464379B1 (en) | Vaccine having a peptide adjuvant for eliciting a specific immune response to treat influenza viral infection | |
| AU2002309245B2 (en) | Vaccines including as an adjuvant type 1 IFN and processes related thereto | |
| JP2008526985A (ja) | 粘膜ワクチンの送達のためのペプチド | |
| CN102085366B (zh) | 一种复合疫苗佐剂 | |
| EP2632483A2 (en) | Immunogenic composition | |
| HK1170669B (en) | Alpha thymosin peptides as vaccine enhancers | |
| KR20220054590A (ko) | 비강에 바이러스 특이적 항체를 유도 가능한 계절성 인플루엔자 백신 | |
| RU2776479C1 (ru) | Живая пробиотическая вакцина, содержащая консервативные эпитопы вируса гриппа А (LAH+4M2e), для профилактики гриппозной инфекции | |
| CN103458681A (zh) | 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽 | |
| Park et al. | Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant | |
| RU2757013C2 (ru) | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения | |
| WO2023211281A1 (en) | Antiviral vaccine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140911 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150320 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150320 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20150507 |